Experience

Debiopharm

• Switzerland
• Pharmaceutical Manufacturing
• 300 - 400 Employee

• Scientist, Translational Medicine/PMed

  • Jan 2023 - Present

• Associate Scientist, Translational Medicine/PMed

  • Sep 2021 - Dec 2022

• Scientific Fellow in Biomarker Development

  • Sep 2020 - Aug 2021



Friedrich Miescher Institute for Biomedical Research

• Switzerland
• Research Services
• 100 - 200 Employee

• Postdoctoral Researcher

  • Jan 2020 - Sep 2020

  Interim PostDoc position supporting an ongoing project with focus on data mining and validation studies of CRISPR screens in mammalian cancer cells in Susan Gasser`s lab. Interim PostDoc position supporting an ongoing project with focus on data mining and validation studies of CRISPR screens in mammalian cancer cells in Susan Gasser`s lab.



Novartis

• Switzerland
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Postdoc

  • Sep 2015 - Aug 2019

  PostDoc project in Drug Development Biology. CRISPR sensitizer screens in human melanoma cells to identify novel factors to improve p53-reactivation-based cancer therapies. Screening experience includes wetlab, data mining & visualization and validations studies (proliferation assays, RNAi by siRNA/shRNA, RNASeq, proteomics, fluorescent microscopy, flow cytometry). Research on resistance to lipid peroxidation. PostDoc project in Drug Development Biology. CRISPR sensitizer screens in human melanoma cells to identify novel factors to improve p53-reactivation-based cancer therapies. Screening experience includes wetlab, data mining & visualization and validations studies (proliferation assays, RNAi by siRNA/shRNA, RNASeq, proteomics, fluorescent microscopy, flow cytometry). Research on resistance to lipid peroxidation.



Philipps University of Marburg - GERMANY

• Research Services
• 100 - 200 Employee

• PhD student

  • Jan 2009 - Feb 2015

  The first part of my thesis was focused on the characterization of a mouse model overexpressing an oncogenic isoform of p73. The aim was to study the tumor phenotype of this mouse model alone or in combination with further genetic alterations (e.g. loss of p53 or simultaneous expression of oncogenic Ras). The second part consists of the establishment of a novel luciferase based method for validation experiments of target genes found by RNAi screens. This new method allows to monitor tumor… Show more The first part of my thesis was focused on the characterization of a mouse model overexpressing an oncogenic isoform of p73. The aim was to study the tumor phenotype of this mouse model alone or in combination with further genetic alterations (e.g. loss of p53 or simultaneous expression of oncogenic Ras). The second part consists of the establishment of a novel luciferase based method for validation experiments of target genes found by RNAi screens. This new method allows to monitor tumor development of tumor cell mixtures (e.g. unaltered control cells mixed with RNAi treated cells) over time in cell culture as well as in vivo. Especially for xenograft models this method allows to compare precisely the development of the cell mixtures in solid tumors not only by endpoint analyses but during the whole tumor growth. Show less The first part of my thesis was focused on the characterization of a mouse model overexpressing an oncogenic isoform of p73. The aim was to study the tumor phenotype of this mouse model alone or in combination with further genetic alterations (e.g. loss of p53 or simultaneous expression of oncogenic Ras). The second part consists of the establishment of a novel luciferase based method for validation experiments of target genes found by RNAi screens. This new method allows to monitor tumor… Show more The first part of my thesis was focused on the characterization of a mouse model overexpressing an oncogenic isoform of p73. The aim was to study the tumor phenotype of this mouse model alone or in combination with further genetic alterations (e.g. loss of p53 or simultaneous expression of oncogenic Ras). The second part consists of the establishment of a novel luciferase based method for validation experiments of target genes found by RNAi screens. This new method allows to monitor tumor development of tumor cell mixtures (e.g. unaltered control cells mixed with RNAi treated cells) over time in cell culture as well as in vivo. Especially for xenograft models this method allows to compare precisely the development of the cell mixtures in solid tumors not only by endpoint analyses but during the whole tumor growth. Show less



Karlsruhe Institute of Technology (KIT)

• Germany
• Higher Education
• 700 & Above Employee

• Research Assistant

  • May 2004 - Jul 2004

  Supervising tutor in practical course "Physiology of Animals" Supervising tutor in practical course "Physiology of Animals"



Karlsruhe Institute of Technology (KIT)

• Germany
• Higher Education
• 700 & Above Employee

• Research Assistant

  • May 2003 - Jul 2003

  Supervising tutor in practical course "Physiology of Animals" Supervising tutor in practical course "Physiology of Animals"